NEWS
A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides
NanoViricides discusses its development of NV-387, a drug targeting multiple respiratory viruses including COVID, RSV, Influenza, and Bird Flu.
NV-387 has shown superior activity in animal models compared to approved drugs and has completed Phase I trials with no adverse events.
The company is planning Phase II trials for RSV and other indications.
NV-387's biomimicry reduces the likelihood of viral escape and offers a cost-effective approach to pandemic preparedness.
Regulatory compliance audits are ongoing as the Phase I trial site closes.
NanoViricides aims to advance NV-387 through the fastest regulatory paths for approval worldwide.
NV-387 has shown superior activity in animal models compared to approved drugs and has completed Phase I trials with no adverse events.
The company is planning Phase II trials for RSV and other indications.
NV-387's biomimicry reduces the likelihood of viral escape and offers a cost-effective approach to pandemic preparedness.
Regulatory compliance audits are ongoing as the Phase I trial site closes.
NanoViricides aims to advance NV-387 through the fastest regulatory paths for approval worldwide.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1065Followers
68Following
7320Visitors
Follow